Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Pupa, Serenella M."'
Autor:
Castagnoli L; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Iorio E; Core Facilities, NMR Unit, Istituto Superiore di Sanità, Roma, Italy., Dugo M; Functional Genomics and Bioinformatics Core Facility, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale deiTumori, Milan, Italy., Koschorke A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Faraci S; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Canese R; Core Facilities, NMR Unit, Istituto Superiore di Sanità, Roma, Italy., Casalini P; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Nanni P; Laboratory of Immunology and Biology of Metastasis, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Vernieri C; IFOM, FIRC Institute of Molecular Oncology, Milan, Italy.; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Nicola M; Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Morelli D; Laboratory Medicine Unit, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pupa SM; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Journal of cellular physiology [J Cell Physiol] 2019 Feb; Vol. 234 (2), pp. 1768-1779. Date of Electronic Publication: 2018 Aug 21.
Autor:
Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. filippo.pietrantonio@istitutotumori.mi.it., Fucà G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Morano F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gloghini A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Corso S; University of Torino, Department of Oncology and Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Aprile G; Department of Oncology, ULSS8 Berica, San Bortolo General Hospital, Vicenza, Italy., Perrone F; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., De Vita F; Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery, University of Campania 'Luigi Vanvitelli', School of Medicine, Naples, Italy., Tamborini E; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tomasello G; Department of Oncology, ASST Ospedale di Cremona, Cremona, Italy., Gualeni AV; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ongaro E; Department of Oncology, University and General Hospital, Udine, Italy., Busico A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Giommoni E; Medical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Volpi CC; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Laterza MM; Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery, University of Campania 'Luigi Vanvitelli', School of Medicine, Naples, Italy., Corallo S; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Prisciandaro M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Antista M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pellegrinelli A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Castagnoli L; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pupa SM; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pruneri G; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., de Braud F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Oncology and Haemato-Oncology Department, University of Milan, Università degli Studi di Milano, Milan, Italy., Giordano S; University of Torino, Department of Oncology and Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Cremolini C; Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy., Di Bartolomeo M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Mar 01; Vol. 24 (5), pp. 1082-1089. Date of Electronic Publication: 2017 Dec 05.
Autor:
Tagliabue E; Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy. elda.tagliabue@istitutotumori.mi.it, Campiglio M, Pupa SM, Balsari A, Ménard S
Publikováno v:
Journal of the National Cancer Institute. Monographs [J Natl Cancer Inst Monogr] 2011; Vol. 2011 (43), pp. 82-5.
Autor:
Giordano GG; Istituto di Anatomia Patologica, Facoltà di Medicina, II Università di Napoli, Napoli, Italy. giacomogiordano@libero.it, Tagliabue E, Pupa SM
Publikováno v:
Journal of cellular physiology [J Cell Physiol] 2004 Mar; Vol. 198 (3), pp. 343-9.
Autor:
Rossella Canese, Elda Tagliabue, Patrizia Nanni, Egidio Iorio, Daniele Morelli, Massimo Di Nicola, Simona Faraci, Patrizia Casalini, Lorenzo Castagnoli, Matteo Dugo, Claudio Vernieri, Ada Koschorke, Serenella M. Pupa
Publikováno v:
Journal of Cellular Physiology
Despite different molecular tumor profiles indicate that human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) levels mirror HER2 addiction and trastuzumab benefit in HER2-positive breast cancer (BC), the identification of noninvasive
Autor:
Gianluca Tomasello, Giovanni Fucà, Silvia Giordano, Maria Antista, Federica Morano, Lorenzo Castagnoli, Serenella M. Pupa, Filippo de Braud, Giancarlo Pruneri, Chiara Costanza Volpi, Ferdinando De Vita, Michele Prisciandaro, Simona Corso, Giuseppe Aprile, Adele Busico, Maria Maddalena Laterza, Elena Ongaro, Salvatore Corallo, Maria Di Bartolomeo, Ambra Vittoria Gualeni, Elena Tamborini, Elisa Giommoni, Filippo Pietrantonio, Federica Perrone, Annunziata Gloghini, Chiara Cremolini, Alessandro Pellegrinelli
Purpose: Refining the selection of HER2-positive metastatic gastric cancer patient candidates for trastuzumab is a challenge of precision oncology. Preclinical studies have suggested several genomic mechanisms of primary resistance, leading to activa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::451763540a7d6b97cf3ddc86425c71f4
http://hdl.handle.net/11568/901565
http://hdl.handle.net/11568/901565